Abstract Number: 735 • 2016 ACR/ARHP Annual Meeting
Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on Response to Adalimumab (HUMIRA) in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) patients (pts) were found to respond better to TNF inhibitors (TNFi) if treated early in the disease course. The objective of…Abstract Number: 1674 • 2016 ACR/ARHP Annual Meeting
Do TNF Inhibitors Change the Progression of Sacroiliitis?
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting the sacroiliac (SI) joints and spine causing structural changes seen on clinical radiography. Studies have…Abstract Number: 2714 • 2016 ACR/ARHP Annual Meeting
Association of Polymorphisms of Activation-Induced Cytidine Deaminase with Ankylosing Spondylitis
Background/Purpose: There was a biased repertoire of the immunoglobulin (Ig) heavy chain variable (VH) segment gene in B cells in patients with ankylosing spondylitis (AS).…Abstract Number: 685 • 2016 ACR/ARHP Annual Meeting
Paradoxical Psoriasis Secondary to Anti-Tnfa Agents in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Cohort Study
Background/Purpose: Anti-tumor necrosis factor-alpha (anti-TNFa) agents are established as the mainstay of treatment for ankylosing spondylitis (AS). Recently, paradoxical induction or exacerbation of psoriatic skin…Abstract Number: 736 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open Label, Randomized Clinical Tries of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Ankylosing Spondylitis
Background/Purpose: To compare the clinical、radiographic and magnatic resonance imaging change in active ankylosing spondylitis patients with etanercept and celecoxib alone/combined treatment,and to evaluate the effectiveness…Abstract Number: 1676 • 2016 ACR/ARHP Annual Meeting
Methotrexate and Anti-Tumor Necrosis Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Background/Purpose: Inflammatory rheumatic diseases (IRDs) are associated with accelerated atherosclerosis, which progression is related to inflammation (1). One of the first stages in atherogenesis is…Abstract Number: 2715 • 2016 ACR/ARHP Annual Meeting
Genetic Variants in TNF, TNFRSF1A, and IL23R Are Associated with Risk of Ankylosing Spondylitis
Background/Purpose: The objective of this study was to evaluate single nucleotide polymorphisms (SNPs) involved in TNFα signaling, NF-κB activation, interferon-γ signaling, or pattern recognition receptor…Abstract Number: 686 • 2016 ACR/ARHP Annual Meeting
Development and Evaluation of the Combined Ankylosing Spondylitis Spine Score (CASSS) for the Assessment of Spinal Radiographic Outcome
Background/Purpose: Spinal radiographic progression is a highly variable process in ankylosing spondylitis (AS). Our aim was to develop a combined AS spine score (CASSS) in…Abstract Number: 910 • 2016 ACR/ARHP Annual Meeting
Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study
Background/Purpose: Recent studies have shown an increase in cardiovascular and all-cause mortality in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).1 The hypothesized dual role of…Abstract Number: 1728 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease
Background/Purpose: Psoriatic arthritis (PsA), Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are an inflammatory arthritis causing joint damage and disability. Non-adherence to disease modifying anti-rheumatic…Abstract Number: 2736 • 2016 ACR/ARHP Annual Meeting
Do Validated Tools of Disease Activity in Ankylosing Spondylitis Measure Fibromyalgia Pain?
Background/Purpose: Concomitant fibromyalgia syndrome (FMS) is a common problem in ankylosing spondylitis (AS) and its recognition is important for optimal management. BASDAI, a disease activity…Abstract Number: 5L • 2015 ACR/ARHP Annual Meeting
Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomized, Placebo-Controlled, Dose-Ranging Study
Background/Purpose: This was the first investigation of the effects of tofacitinib (TOFA) in adult patients (pts) with active ankylosing spondylitis (AS). TOFA is an oral…Abstract Number: 6L • 2015 ACR/ARHP Annual Meeting
Effect of Interleukin-17A Inhibition on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of a Phase 3 Study with Secukinumab
Background/Purpose: In the MEASURE 1 trial (NCT01358175), secukinumab significantly improved the signs and symptoms of patients (pts) with active ankylosing spondylitis (AS) over 52 weeks…Abstract Number: 671 • 2015 ACR/ARHP Annual Meeting
Discrepancy Between Patients and Physicians Acceptable Symptomatic States in Axial Spondyloarthritis: Findings from the RAPID-AxSpA Study
Background/Purpose: Discordance between patient (pt) and physician (phy) assessment of disease activity (DA) in spondyloarthritis (SpA) is recognized, with phys tending to score DA less…Abstract Number: 1700 • 2015 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis in Ankylosing Spondylitis. Does It Really Exist and Which Are the Effects of Treatments? a Systematic Review
Background/Purpose: Accelerated atherosclerosis and increased cardiovascular morbidity and mortality have been associated with ankylosing spondylitis (AS). Noninvasive angiological methods have been developped to evaluate endothelial…
- « Previous Page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- …
- 57
- Next Page »